AC Immune to receive milestone payment from Genentech
Posted on 02.11.2017 in Company Highlight, News
02.11.2017 Genentech has dosed the first patient in a Phase 2 clinical trial for Alzheimer’s disease (AD) with an anti-Tau monoclonal antibody known as RO7105705. Upon the dosing of the first patient in the Phase 2 clinical trial, AC Immune becomes eligible to receive a milestone payment of CHF 14 million.
